Human milk oligosaccharides (HMOs) are recognized as benefiting breast-fed infants in multiple ways. As a result, there is growing interest in the synthesis of HMOs mimicking their natural diversity. Most HMOs are fucosylated oligosaccharides. α-L-Fucosidases catalyze the hydrolysis of α-L-fucose from the non-reducing end of a glucan. They fall into the glycoside hydrolase GH29 and GH95 families. The GH29 family fucosidases display a classic retaining mechanism and are good candidates for transfucosidase activity. We recently demonstrated that the α-L-fucosidase from Thermotoga maritima (TmαFuc) from the GH29 family can be evolved into an efficient transfucosidase by directed evolution (Osanjo et al. 2007) . In this work, we developed semi-rational approaches to design an α-Ltransfucosidase starting with the α-L-fucosidase from commensal bacteria Bifidobacterium longum subsp. infantis (BiAfcB, Blon_2336). Efficient fucosylation was obtained with enzyme mutants (L321P-BiAfcB and F34I/L321P-BiAfcB) enabling in vitro synthesis of lactodifucotetraose, lacto-N-fucopentaose II, lacto-N-fucopentaose III and lacto-N-difucohexaose I. The enzymes also generated more complex HMOs like fucosylated para-lacto-N-neohexaose (F-p-LNnH) and mono-or difucosylated lacto-N-neohexaose (F-LNnH-I, F-LNnH-II and DF-LNnH). It is worth noting that mutation at these two positions did not result in a strong decrease in the overall activity of the enzyme, which makes these variants interesting candidates for large-scale transfucosylation reactions. For the first time, this work provides an efficient enzymatic method to synthesize the majority of fucosylated HMOs.
Introduction
Originally identified as the "bifidus factor" (Gyorgy et al. 1954) , human milk oligosaccharides (HMOs) are recognized as benefiting breast-fed infants in multiple ways. First, HMOs are generally accepted as exhibiting prebiotic activity (Roberfroid, 2007) as metabolic substrates for beneficial bacteria and providing them with a growth advantage over potential pathogens in the colon (Asakuma et al. 2011) . There is also evidence suggesting that HMOs have antiadhesive properties as soluble decoy receptors, preventing pathogen attachment and lowering the risk for bacterial, viral and protozoan infections (Ruiz-Palacios et al. 2003; Morrow et al. 2005) . They also directly affect intestinal epithelial cells and modulate their gene expression, which leads to changes in cell surface glycans and other cell responses (Angeloni et al. 2005; Kuntz et al. 2009 ). HMOs can modulate lymphocyte maturation and cytokine production, potentially leading to a more balanced immune response (Eiwegger et al. 2010) . They reduce selectin-mediated cell-cell interactions in the immune system and decrease leukocyte rolling on activated endothelial cells, potentially leading to reduced mucosal leukocyte infiltration and activation (Bode et al. 2004) . It has been shown that HMOs also provide sialyl groups, potentially essential nutrients for brain development and cognition (Wang et al. 2007) .
More than 200 different HMOs have been identified so far, but not every woman synthesizes the same set of oligosaccharides (Kobata, 2010) as the amount and composition may vary between women (Kunz et al. 2000) . HMOs are composed of five different monosaccharides: D-glucose (Glc) , D-galactose (Gal) , N-acetylglucosamine (GlcNAc), L-fucose (Fuc) and sialic acid (N-acetylneuraminic acid, Neu5Ac). They always contain the disaccharide lactose (Galβ(1,4) Glc) at their reducing end. Chain elongation occurs by attachment of two types of disaccharide: lacto-N-biose (Galβ(1,3)GlcNAc) and N-acetyllactosamine (Galβ(1,4)GlcNAc) forming the different HMO core structures. These core oligosaccharides are further decorated with fucosyl and/or sialic acid residues. Fucosylated HMOs are formed by attachment of fucose residues in α(1,2) position to terminal Gal residues, in α(1, 3) position to the Glc unit at the reducing end or in α(1,3) or α(1,4) positions to the GlcNAc moieties. Fucosylated oligosaccharides make up the majority of HMOs (>50%), at least for women with active secretor loci (SE gene encoding the α(1,2)-fucosyltransferase FUT2 and LE gene encoding the α(1,3/4)-fucosyltransferase FUT3). In contrast, non-secretors lack a functional FUT2 enzyme and their milk does not contain α(1,2)-fucosylated HMO. Milk of LE-negative women lacks these specific α(1,4)-fucosylated HMOs, e.g., LNFP-II. Due to the multiple potential beneficial effects of HMOs on infants, there is growing interest in the synthesis of HMOs mimicking their natural diversity. The bottleneck in HMO research is mainly the limited availability of HMO resources needed to understand better the underlying mechanisms of their action and to confirm that the observed effects translate into measurable health benefits for the neonate. Human milk tri-and tetrasaccharides have recently become available in sufficient quantities to move forward (Drouillard et al. 2006 (Drouillard et al. , 2010 . However, structurally more complex HMOs ( penta-or hexasaccharides) are not available and yet are needed to study their significant health benefits and to complete the HMO research. Hence, the aim of this work was to design transfucosidases from fucosidases to decorate HMOs and have access to a diversity of fucosylated HMOs corresponding to those encountered in human milk. 
Average concentration of HMOs based on different studies (Coppa et al. 1999; Kunz et al. 2000; Chaturvedi et al. 2001; Asakuma et al. 2008; Thurl et al. 2010 ).
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Percentage not calculated because lactose is not considered an HMO. α-L-Fucosidases are exo-acting glycoside hydrolases that catalyze the hydrolysis of α-L-fucose from the non-reducing end of a glucan. They fall into the glycoside hydrolase GH29 and GH95 families of the CAZy sequence-based classification. GH29 family fucosidases display a classic retaining mechanism with retention of an anomeric configuration, involving double displacement of the O-fucosyl bond through sequential enzyme glycosylation and hydrolysis steps (Tarling et al. 2003) . In contrast, α-L-fucosidases from GH95 proceed via an Scheme 1. Structure of the compounds involved in enzymatic fucosylation of HMO by BiAfcB and its mutants with 3FL as fucosyl donor. The HMO backbone is drawn in black, Fucα(1,4) on GlcNAc in red, Fucα(1,3) on GlcNAc in blue, Fucα(1,3) on Glc in purple, Fucα(1,2) on Gal in dark green. This figure is available in black and white in print and in color at Glycobiology online.
inverting mechanism. Due to these mechanistic differences, only fucosidases from GH29 are good candidates for transfucosidase activity. We recently demonstrated that the α-L-fucosidase from Thermotoga maritima (TmαFuc) from the GH29 family could be evolved into an efficient transfucosidase by directed evolution (Osanjo et al. 2007) and may thus constitute an efficient enzymatic tool for in vitro synthesis of fucosylated oligosaccharides.
In this work, we developed semi-rational approaches to design an α-L-transfucosidase starting with the α-L-fucosidase from Bifidobacterium longum subsp. infantis (BiAfcB). Efficient fucosylation was obtained with enzyme mutants enabling in vitro synthesis of lactodifucotetraose (LDFT), lacto-N-fucopentaose II (LNFP-II), lacto-Nfucopentaose III (LNFP-III) and lacto-N-difucohexaose I (LNDFH-I). The enzymes can also generate more complex HMOs like fucosylated para-lacto-N-neohexaose (F-p-LNnH) and mono-or difucosylated lacto-N-neohexaose (F-LNnH-I, F-LNnH-II and DF-LNnH) ( Table I and Scheme 1).
Results

Selection of a suitable fucosidase
Recent studies have shown that hydrolysis of the HMO fucosyl linkages by Bifidobacterium bifidum from infant gut microbiota involves two α-L-fucosidases with different specificities. One is an α (1,2)-L-fucosidase (BbAfcA) that belongs to the GH95 family (Katayama et al. 2004; Nagae et al. 2007) , and the other is an α(1,3/ 4)-L-fucosidase (BbAfcB) belonging to the GH29 family (Ashida et al. 2009; Sakurama et al. 2012 ). The α(1,2)-L-fucosidase (BbAfcA) is an inverting glycosidase, which is not suitable for the transglycosidase reaction. As an alternative, we have previously shown that some variants of the α(1,2)-L-fucosidase from T. maritima (TmαFuc) can transfer the α-fucosyl residue with 1,2 regioselectivity (Osanjo et al. 2007) . When the best transfucosidase variant (P25) of this study was tested in the presence of 2′-O-fucosyllactose (2′FL) as a donor and LNT as an acceptor, the main transglycosidase product (13%) was Fucα(1,3)Galβ(1,3)GlcNAcβ(1,3)Galβ(1,4)Glc (Fucα(1,3)LNT) together with a minor product (1%) (Supplementary data, Figure S2 ). As Fucα(1,3)LNT has not been identified as an HMO (Supplementary data, Table SXII), this fucosidase was not chosen for further engineering.
The α-fucosidase from B. longum subsp. infantis (ATCC 15697), BiAfcB (or Blon_2336) belongs to the GH29-B subfamily like BbAfcB (Sakurama et al. 2012) . Sequence identity between BbAfcB and BiAfcB is low (13% over the entire sequence and 33% over the most homologous sequence part). However, the residues involved in substrate binding are essentially conserved thus reflecting the same substrate specificity. Moreover, the crystal structures of BiAfcB in complex with LNFP-II (an HMO) have been determined (Sela et al. 2012) . As this enzyme is a retaining glycoside hydrolase, it has the potential to be evolved into a transfucosidase according to our previous results (Osanjo et al. 2007 ). For these reasons, BiAfcB was chosen as a base for the development of an α-L-transfucosidase to synthesize HMOs.
Conversion of BiAfcB into an α(1,3/4)-transfucosidase by site-directed mutagenesis
BiAfcB is a fucosidase that preferentially cleaves α(1,3) and α(1,4) linkages such as those present in LNFP-II and LNFP-III, respectively (Table I) , and has a small activity on the α(1,2) linkage (Sela et al. 2012 ). The wild-type enzyme has a small transfucosidase activity, which was demonstrated by using 3FL as donor and LNT as acceptor (Table II) . The enzyme is capable of transferring the fucosyl residue from 3FL to LNT to produce LNFP-II and lactose as a by-product. When the substrates were reacted at 20 mM, LNFP-II was formed with a maximum yield of 6%. The time course of the transfucosylation reaction was also observed at higher concentrations of donor and acceptor (200 mM) leading to greater conversion (12%). Hydrolysis of both the donor and the product competes with the transglycosylation reaction preventing the accumulation of LNFP-II ( Figure 1) . Thus, the objective was to improve the α(1,3/4)-transfucosidase activity of BiAfcB by increasing the transglycosylation/hydrolysis activity ratio (T/H).
Previous work (Osanjo et al. 2007 ) on the evolution of TmαFuc identified at least three mutations (T264A, Y267F and L322P) that dramatically improved the transglycosidase activity. Despite the fact that TmαFuc and BiAfcB enzymes do not belong to the same GH29 subfamilies (GH29-A and GH29-B, respectively, Sakurama et al. 2012) , which results in low sequence identity (26%), the catalytic domain of BiAfcB (3UES, Sakurama et al. 2012 ) aligns well structurally with that of TmαFuc (2ZXD, Wu et al. 2010 ) and most of the activesite residues are conserved. Structural alignment ( Figure 2 ) identified residue L322 from TmαFuc as homologous to residue L321 from BiAfcB because these residues belong to the β8 secondary structure of the TIM barrel fold and are strictly superimposed. However, no structurally homologous residues of TmαFuc Y267 and T264 were identified in BiAfcB. Although TmαFuc Y264 formally corresponds to BiAfcB W213 inside the TIM barrel β6 secondary structure (Supplementary data, Figure S3 ), the side-chain orientations and shapes are too different. Finally, TmαFuc Y267 belongs to the loop joining β6 and α6 secondary structure elements while the corresponding loop in BiAfcB is not superimposable, preventing any structural homology in BiAfcB. Only residue L321-BiAfcB presents real homology with L322-TmαFuc. Residue L321-BiAfcB was mutated into proline and the transglycosylation activity of the mutated enzyme was measured (Table II and Figure 1) .
The transfucosidase activity of the L321P-BiAfcB mutant was examined using 3FL as the fucosyl donor and LNT as acceptor at 20 and 200 mM in a 1:1 molar ratio (Table II) . The time course of the substrate and product formation was followed by HPLC (Figure 1 ) to determine the transient maximum percentage for the conversion of acceptor (LNT) into product (LNFP-II). The mutant L321P-BiAfcB improved the transfucosylation yield from 6% for WT-BiAfcB to 8% for L321P-BiAfcB at 20 mM and from 12% for WT-BiAfcB to 28% for L321P-BiAfcB at 200 mM (Table II and Figure 1 ). After purification of the transglycosylation product, NMR structural determination confirmed that the only product was LNFP-II (Scheme 1 and Supplementary data, Table SVII ). However, although the transfucosylation reaction was predominant in the first phase of the reaction, the mutant L321P-BiAfcB presented significant secondary hydrolysis of the product, which limited the transfucosylation yield (Figure 1 ).
Evolution of the α(1,3/4)-transfucosidase
In order to reduce the secondary hydrolysis reaction, we targeted the most conserved residues of the −1 site according to the approach that we recently proposed to improve the transglycosylation/hydrolysis activity ratio (Teze et al. 2014) . Six positions within the −1 site were highly conserved within the subfamily GH29-B (Supplementary data, Figure S3 ). Two residues (H36, Y131) were located in the first shell and four residues (F34, E46, W170, and F291) were in the second shell (Supplementary data, Figure S4 ). The effect of the selected mutations (F34Y/S, H36N/I, E46Q/A, Y131F, W170F/A, and F291S) on transfucosidase activity was screened by thin-layer chromatography (TLC) in the presence of 3FL and LNT as donor and acceptor, respectively. Only mutations on position F34 gave a detectable improvement in the transglycosylation activity of the L321P-BiAfcB mutant. This position was thus chosen to explore further the effect of alternative amino acid mutations (A, W, Y, H, and I, Supplementary data, Figure S5 ), which selected on the basis of their conservative properties and steric hindrance. After TLC screening, quantitative measurements of the transglycosylation reaction were carried out by capillary electrophoresis (Table II and Supplementary data, Figure S6 ) at 20 mM and HPLC at 200 mM substrate concentrations (Figure 3 ). L321P/F34I-BiAfcB presented the best performance in terms of the transfucosylation reaction with an LNFP-II yield of 17% against 8% for L321P-BiAfcB and 6% for WT-BiAfcB at 20 mM substrate concentrations. The kinetic study (Figure 1) showed that the additional F34I mutation provided a strong reduction in the secondary hydrolysis activity on the reaction product LNFP-II and a slight increase in the transfucosylation yield from 28% (L321P-BiAfcB) to 32% (L321P/F34I-BiAfcB) for 200 mM of donor and acceptor.
Acceptor promiscuity of the new α(1,3/4)-transfucosidases
The L321P/F34I-BiAfcB double mutant was then tested for the synthesis of various fucosylated HMOs. The transfucosylation yield of LNFP-II, LNFP-III, LDFT and LNDFH-I in the presence of 3FL as a donor and LNT, LNnT, 2′FL and LNFP-I as acceptors, respectively, was determined by capillary electrophoresis (Table III and Supplementary data, Figure S6 ). The yields obtained for each fucosylated HMO were similar (17% for LDFT and LNFP-II and 21% for LNFP-III) whereas the difucosylated LNT, LNDFH-I, was obtained with 11% yield. For each synthesis, only one major product was obtained, whose structure was confirmed by NMR and MS/MS (Supplementary data, Tables SVII-SX).
The L321P-BiAfcB single mutant was also used to generate the other fucosylated HMO products (LNFP-II, LNFP-III, LDFT, LNDFH-I, F-p-LNnH, F-LNnH-I, F-LNnH-II and DF-LNnH) with the corresponding acceptors (Table I) . A sufficient quantity (10-100 mg) of each fucosylated product was obtained to enable purification by reverse phase chromatography and structural characterization by NMR (Supplementary data, Tables SVII-SXI) and/or MS/MS (Supplementary data, Tables SXIII-SXV) .
Taken together, these results demonstrate that these new mutated transfucosidases have a sufficiently broad specificity to enable the synthesis of a wide range of fucosylated HMOs.
Discussion
The α(1,3/4)-fucosidase BiAfcB has an interesting catalytic property since it hydrolyses branched α-fucose residues on HMOs, while being inactive on terminal α-fucose linkages and hardly active on pNP-fuc (Ashida et al. 2009; Sela et al. 2011) . Based on previous strategies that we developed to convert glycosidases into transglycosidases (Osanjo et al. 2007; Teze et al. 2014) , we have demonstrated that the transglycosidase activity of BiAfcB can be significantly improved by a semi-rational mutagenesis approach. The best mutants were able to synthesize branched fucosyl HMO (LNFP-II) with yields up to 30% ) and BiAfcB (PDB accession numbers: 2ZXD, GH29B) and location of L322, T264 and Y267 (TmαFuc) residues and L321 (BiAfcB) residue. Amino acids of TmαFuc are in ball and stick representation; amino acids of BiAfcB are in stick representation. β6 and β8 strands of TmαFuc in gray. β6 and β8 strands of BiAfcB in white. α6 helix of TmαFuc in blue. α6 helix of BiAfcB in cyan. β6-α6 loop of TmαFuc in dark green. β6-α6 loop of BiAfcB in pale green. This figure is available in black and white in print and in color at Glycobiology online.
using the non-activated donor 3FL as a substrate and an acceptor/ donor ratio of one. This result is particularly significant since the maximum theoretical yield for transglycosylation in the presence of a nonactivated donor substrate (in which the aglycon part is not a fluoride or a pNP) and with a 1:1 acceptor:donor ratio should not exceed 50% in the absence of a competing hydrolysis reaction. As an alternative to the synthesis of an α(1,3/4)-fucosyl HMO, the glycosynthase strategy was recently tested on the homologous α-L-fucosidase (BbAfcB) enzyme by mutating the nucleophilic residue D703 into a serine and using β-L-fucosyl fluoride as a donor (Sakurama et al. 2012 ). The maximum yield reported for the synthesis of LNFP-II was 41% with a 2.5 M excess of LNT acceptor. A severe limitation of this approach is that the donor substrate is extremely unstable with a half-life of 20 min. In this respect, the present transfucosidase approach for the synthesis of fucosylated HMOs has a strong advantage since it relies on a natural donor substrate (3FL) and the only by-product of the reaction is the lactose formed by both the competing hydrolysis and the transglycosylation reactions.
Mutations that improve the transfucosylation yield of BiAfcB were selected by two-step semi-rational approaches. The first improved mutant L321P was suggested by a previous work on the directed evolution of the α-fucosidase from T. maritima (Osanjo et al. 2007 ) and identified by its structural homology to L322P in TmαFuc. Despite the fact that these two α-fucosidases belong to different groups (A and B) in GH29 with consequently low sequence identity (24%), the L321/322 position is located in the middle of a well-conserved β-barrel. The reason for the strong effect of this mutation on the transfucosylation yield is difficult to rationalize since it lies in the second sphere of the −1 site and is highly conserved (100%) in the GH29 family. According to our recent results Teze et al. (2014 Teze et al. ( , 2015 showed that targeting highly conserved residues around the −1 site of GH1 and GH36 families improves the probability of sorting transglycosidase mutants, we explored additional positions in the first shell (H36, Y131) and in the second shell (F34, E46, W170, F291). Only mutation on the F34 position gave a significant improvement in the transfucosidase properties of the L321P mutant, mainly by strongly reducing the secondary hydrolysis of the product (Figure 1) . Interestingly, this position is located just between the L321P mutation and the substrate at the bottom of the −1 site. This suggests that the hydrophobic residues located at the bottom of the −1 site, in close proximity to the CH 3 group of fucose, are important for positioning the fucosyl part of the substrate and for the control of the transglycosylation/hydrolysis ratio. It is worth noting that mutation at these two positions did not result in a strong decrease in the overall activity of the enzyme, which makes these variants interesting candidates for large-scale transfucosylation reactions.
These improved transfucosidase mutants (L321P, L321P/F34I) were also able to fucosylate various HMOs (LNT, LNnT, 2′FL, LNFP-I, LNnH, p-LNnH, F-LNnH, Table I ) to give mono-and di-fucosylated HMOs in significant yields (10-20%) even at low donor/acceptor concentration (20 mM). Starting from 3FL, this mutant enabled access to 8 of the most common fucosylated HMOs (LNFP-II, LNFP-III, LDFT, LNDFH-I, F-p-LNnH, F-LNnH-I, F-LNnH-II and DF-LNnH). Moreover, due to the high linkage specificity of this transfucosidase, only one fucosylated product was synthesized with each acceptor, a property that was also observed with the corresponding glycosynthase (Sakurama et al. 2012 ).
Materials and methods
Gene cloning
The gene Blon_2336, which encodes an α-L-fucosidase named BiAfcB, was amplified by polymerase chain reaction (PCR) from genomic DNA of B. longum subsp. infantis strain ATCC ® 15697™ using the primers Blon_2336_for (5′-AGATTCATTAGAATTCCATATGAAC AATCCTGCAGATGCGGGCATC-3′) and Blon_2336_rev (5′-ACA TACATGCAAGCTTTCAGTGGTGGTGGTGGTGGTGGATGCG CACGGCAGCCGCGCGGCTGAT-3′), which carry the EcoRI and HindIII restriction sites, respectively. The sequences recognized by the enzymes are underlined. The sequence encoding for Histidine-tag (6× His) is added by PCR and the sequence is in bold letters. Twenty picomoles of each primer were mixed with 50 ng of genomic DNA (ATCC ® 15697™) in a 50 µL PCR. The reaction conditions were 5 µL 10× Pfu buffer with 20 mM MgSO 4 , 0.16 mM for dATP and dTTP, 0.24 mM for dGTP and dCTP, and 2.5 units of Pfu DNA polymerase (ThermoScientific). The reaction was thermocycled as follows: 95°C for 3 min, and then 30 cycles at 95°C for 45 s; 57°C for 30 s and 72°C for 6 min and finally one cycle at 72°C for 10 min. These PCR products were digested by EcoRI and HindIII restriction enzymes and cloned into the pBTac2 plasmid digested by the same enzyme. The expression vector containing the ORF Blon_2336 that encodes BiAfcB under the control of the Ptac promoter was termed pBBiAfcB. The plasmid pBBiAfcB was introduced into E. coli XL1Blue cells to express enzymes.
Site-directed mutagenesis
Around 20 pmol of mutagenic primers (Supplementary data, Table SI) was mixed with 50 ng of plasmid pBBiAfcB vector for mutagenesis of BiAfcB (described previously) in a 50-µL PCR. The reaction conditions were 5 µL 10× Pfu buffer with 20 mM MgSO 4 , 0.2 mM each dNTP and 2.5 units of Pfu DNA polymerase (ThermoScientific). The reaction was thermocycled as follows: 95°C for 30 s, and then 16 cycles at 95°C for 30 s, 55°C for 1 min and 68°C for 7 min. PCR products were digested by DpnI restriction enzymes. The resulting plasmids were transformed into competent XL1 blue cells. The open reading frame encoding each mutant enzyme was sequenced in both forward and reverse directions.
Production, extraction and purification of WT and mutant enzymes
Recombinant strains expressing the BiAfcB mutant genes were grown in 1 L of LB medium at 37°C to 0.7 of OD 600nm and IPTG at 0.5 mM was added to induce the expression at 30°C overnight. Then the culture was centrifuged and the pellet was resuspended in 20 mL of lysis buffer (0.1 M phosphate, pH 8, 0.5 M NaCl, 10 mM imidazole). After sonication and centrifugation, the 6 His-tagged proteins were purified by immobilized ion metal-affinity chromatography: 300 µL of Ni-NTA Superflow (Qiagen) was added to the supernatant and stirred for 1 h at 4°C, then loaded onto a 10-mL column. The column was washed using 25 mL of washing buffer (0.1 M phosphate, pH 8, 0.5 M NaCl, 25 mM imidazole), then 5-fold 500 µL of elution buffer was added (0.1 M phosphate, pH 8, 0.5 M NaCl, 250 mM imidazole). In some cases, the imidazole was removed using desalting PD10 columns (GE Healthcare). The purity of the final product was checked by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Enzyme concentrations were determined by UV absorbance at 280 nm using a NanoDrop 1000 (ThermoScientific) with ε = 99 100.00 cm −1 M −1 . The expression yield varied between 1 and 5 mg/ L of culture depending on the expressed mutant.
Molecular modeling
Tridimensionnal superimposition of TmαFuc and BiAfcB structures could not be obtained by any available pairwise sequence alignment method (Supplementary data, Figure S3 ) since very large gaps are encountered between sequences (i.e., β1-α1 and α6-β7 loops). Then, to superimpose TmαFuc and BiAfcB, highly accurate 3D structures were selected 2ZXD for TmαFuc (Wu et al. 2010 ) and 3UES for BiAfcB (Sakurama et al. 2012 ). Due to the core location of parallel β-strands in TIM barrel structure, it is convenient to superimpose these two structures by fitting selected pairs of Cα belonging to inner β-strands. For the sake of symmetry, two Cα atoms from each β-strand of the two molecules were chosen, leading to 16 pairfittings (Figure 2 and Supplementary data, Figure S3 ). As a result of the relevance of this protocol, the other architectural elements (eight outer α-helices of the TIM barrel fold) were also superimposed. More interestingly, the catalytic residues of both fucosidases were satisfactorily superimposed leading to the overall conservation of the catalytic site shapes.
Enzymatic transfucosylation
The HMO substrates used in the enzymatic reactions were provided by Glycom A/S. For the BiAfcB enzyme and its mutants, kinetic reactions were performed at 37°C in a volume of 200 µL in NaH 2 PO 4 100 mM ( pH 7) reaction buffer. The 3FL was used as the donor at 200 mM and the LNT as the acceptor at 200 mM. Reactions were followed by HPLC at different time points (typically 0 min, 15 min, 30 min, 1 h, 2 h, 3 h, 5 h and 24 h) by taking 10 µL aliquots of the reaction mixture and quenching with cold ACN. HPLC analyses were performed with a TSK Gel amide 80 column (Tosoh, 3 µm, 150 × 4.6 mm) using 56% acetonitrile and 44% water as eluent with a flow of 1 mL/min. The elution of substrates and products was detected by CAD and/or UV detection at 195 nm. Quantification of substrates and products was performed using calibration curve made from reference compounds. Reference substance for substrates was provided by Glycom A/S. Reference substance for products was prepared in the present study (see Preparative synthesis of the new fucosylated HMO products) For the lower concentrations of acceptor and donor, the enzymatic transfucosylation experiments were carried out with purified enzymes at decreasing concentrations ( performed by serial dilutions). The reactions with different concentrations of enzyme were stopped at the same time. Eighteen micrograms of BiAfcB purified enzyme (WT or mutants) were mixed with 20 mM of 3FL as donor, 20 mM of LNT as acceptor in reaction buffer NaH 2 PO 4 100 mM ( pH 6) and incubated for 3 h at 37°C. Before quantifying the transglycosylation products by capillary electrophoresis, the best mutants were screened by TLC (Supplementary data, Figure S4 ). One microliter of each reaction medium was loaded onto silica gel plates (TLC silica gel 60 F 254 , Merck) and products were separated in 5/5/3 (v/v/v) butanol/ethanol/H 2 O eluent. After separation, the TLC plate was dried, then bathed in 0.1% (w/v) orcinol, 10% (v/v) sulfuric acid. The oligosaccharides were revealed by warming at 165°C for between 30 s and 1 min.
Prior to capillary electrophoresis analysis, products of transfucosylation reactions with 2′FL as acceptor were labeled with 4-aminobenzonitrile by reductive amination (Paulus and Klockow, 1996) . NaCNBH 3 was purified by filtration of a 1 M solution in tetrahydrofuran to eliminate precipitated NaBH 4 . The labeling was carried out by mixing freshly purified NaCNBH 3 (100 mg) with 4-aminobenzonitrile (0.6 g) and acetic acid (0.5 mL) in methanol (10 mL). Twentythree microliters of the reaction mixture were added to 10 µL of sample and incubated at 70°C for 2 h. The reaction medium was 5-fold diluted in 50 mM Borax buffer ( pH 9.3) before analysis by capillary electrophoresis. Quantitative reductive amination was controlled by using different concentration of standard HMOs.
Separation of the reaction products was performed using a Beckman P/ACE System 5000 with an uncoated fused silica capillary 54 cm long with an internal capillary diameter of 120 µm. Separation was carried out in the electro-endo-osmotic mode under the following conditions: voltage, 17 kV; injection pressure, 0.5 psi from cathode; running buffer, 50 mM Borax buffer, pH 10.4. Products were detected and quantified by UV absorbance at 214 nm. Between runs, the capillary was rinsed for 2 min with 100 mM NaOH followed by water for 2 min and then with 50 mM Borax buffer, pH 10.4, for 2 min.
For the transfucosylation reactions with acceptors containing an N-acetyl group (LNT, LNnT, and LNFP-I), the product was directly detected at λ = 214 nm without derivatization. Kinetics of transfucosylation activities with 3FL as donor and LNT, LNnT or LNFPI as acceptor were determined by capillary electrophoresis (Beckman P/ACE MDQ with an uncoated fused silica capillary, 50 cm in length and 75 µm in diameter). Typical experimental conditions were 100 µL of medium containing 20 mM 3FL, 20 mM LNT, LNnT or LNFPI and 30 µL of enzyme in elution buffer (50 mM NaH 2 PO 4 , 300 mM NaCl, 250 mM imidazole, pH 8). After incubation at 37°C in NaH 2 PO 4 100 mM at pH 6 in the capillary electrophoresis apparatus, aliquots of the reaction medium were analyzed every 25 min for 5-24 h. Separation was performed at 13 kV with 50 mM Borax ( pH 10.4) as running buffer. Acceptors and products were detected by UV absorbance at 214 nm. The peak area was used for quantification.
Preparative synthesis of the new fucosylated HMO products
To characterize the products of fucosylation, the synthesis was carried out on a preparative scale using a 10 mL mixture containing 3FL (200 mM), the HMO acceptor (LNT, LNnT, p-LNnH, LNnH, 2′FL or LNFP-I; 50-200 mM), and 0.02-0.03 mg/mL of purified L321P-BiAfcB mutant. The mixture was incubated at 37°C in sodium phosphate buffer (100 mM, pH 7). When an optimal yield was achieved, the reaction was stopped by heating at 60°C for 10 min and then filtered using an Amicon device (10 kDa). Substrates and products were separated and the products were isolated by reversed phase preparative chromatography using a TSK Gel amide 80 column (Tosoh, 10 µm, 300 × 21.5 mm). A mixture of acetonitrile/MQ water (65%/35%) was used as eluent at a constant flow rate of 25 mL/min. Detection of substrates and products was carried out with a refractometer and UV detector. The new HMO peaks were collected separately, concentrated and freeze-dried.
In a similar way, the mutant P25 from T. maritima was used to synthesize Fucα(1,3)LNT from 2′FL and LNT. In this case, the reaction was performed in citrate phosphate buffer (50 mM, pH 5.5) at 60°C.
Product characterization
The structure of the isolated fucosylated HMO products was characterized and confirmed by NMR spectroscopy and/or MS spectrometry. NMR measurements were performed on a 600 MHz Varian VNMR SYSTEM™ or a 600 MHz Bruker Avance III spectrometer. Resonance assignments were made using standard one-and twodimensional 1 H- 1157. 4033, 1139 4033, .3928, 1097 4033, .3835, 1055 4033, .3708, 893.3199, 875.3099, 792.2744 4033, , 774.2639 4033, , 732.2547 4033, , 690.2431 4033, , 544.1864 4033, , 364.1243 LNT (Supplementary data, Table SXII ): due to the limited availability of the isolated samples for the following compounds, CID MS/MS measurement was the method of choice for structure elucidation, sequence analysis and branching pattern determination in negative ion mode.
F-LNnH-I (Supplementary data, 
Supplementary data
Supplementary data for this article are available online at http://gly cob.oxfordjournals.org/.
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